- Home
- DMLP vs AGIO Comparison
DMLP vs AGIO Comparison
Compare DMLP & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- AGIO
- Stock Information
- Founded
- DMLP 2003
- AGIO 2007
- Country
- DMLP United States
- AGIO United States
- Employees
- DMLP N/A
- AGIO N/A
- Industry
- DMLP Oil & Gas Production
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- AGIO Health Care
- Exchange
- DMLP Nasdaq
- AGIO Nasdaq
- Market Cap
- DMLP 1.4B
- AGIO 1.4B
- IPO Year
- DMLP N/A
- AGIO 2013
- Fundamental
- Price
- DMLP $27.90
- AGIO $27.32
- Analyst Decision
- DMLP
- AGIO Buy
- Analyst Count
- DMLP 0
- AGIO 8
- Target Price
- DMLP N/A
- AGIO $56.00
- AVG Volume (30 Days)
- DMLP 80.8K
- AGIO 515.6K
- Earning Date
- DMLP 05-08-2025
- AGIO 05-01-2025
- Dividend Yield
- DMLP 11.43%
- AGIO N/A
- EPS Growth
- DMLP N/A
- AGIO N/A
- EPS
- DMLP 2.03
- AGIO 11.45
- Revenue
- DMLP $166,824,000.00
- AGIO $37,035,000.00
- Revenue This Year
- DMLP N/A
- AGIO $40.62
- Revenue Next Year
- DMLP N/A
- AGIO $216.26
- P/E Ratio
- DMLP $13.69
- AGIO $2.42
- Revenue Growth
- DMLP 12.09
- AGIO 25.96
- 52 Week Low
- DMLP $25.84
- AGIO $23.42
- 52 Week High
- DMLP $34.88
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- DMLP 43.43
- AGIO 41.34
- Support Level
- DMLP $26.97
- AGIO $27.78
- Resistance Level
- DMLP $28.30
- AGIO $31.55
- Average True Range (ATR)
- DMLP 0.71
- AGIO 1.38
- MACD
- DMLP -0.10
- AGIO -0.03
- Stochastic Oscillator
- DMLP 31.21
- AGIO 2.98
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.